Hong Kong Media Stock News

SEHK:636
SEHK:636Logistics

Is KLN Logistics Group’s AI Logistics SaaS Push with SKG Reshaping Its Moat (SEHK:636)?

Smart Kreate Group Limited (SKG) recently announced a collaboration between its newly formed logistics technology group and KEC (Hong Kong) Limited, a subsidiary of KLN Logistics Group, to co-develop AI-powered, cloud-based logistics SaaS platforms for enterprise and SME customers worldwide. This partnership gives KLN Logistics Group access to SKG’s logistics technology and AI optimization capabilities while contributing its own global infrastructure, positioning both parties within the...
SEHK:679
SEHK:679Machinery

Discovering Asian Opportunities: Huationg Global And Two Other Promising Penny Stocks

As global markets navigate a complex landscape, Asian economies remain a focal point for investors seeking growth opportunities. Amidst this backdrop, penny stocks—often smaller or newer companies with potential for significant returns—continue to capture interest. Despite being considered niche investments, these stocks can reveal hidden value when supported by strong financial health and clear growth trajectories.
SEHK:1883
SEHK:1883Telecom

Did the CFO and Executive Director’s Exit Just Shift CITIC Telecom International Holdings’ (SEHK:1883) Investment Narrative?

CITIC Telecom International Holdings announced that Chief Financial Officer and Executive Director Mr. Luan Zhenjun resigned from both roles on January 30, 2026, citing other work arrangements and prompting a search for his replacement. This simultaneous departure from the finance leadership and the board raises questions about continuity in financial oversight and decision-making at the company. We will now examine how the resignation of the long-serving Chief Financial Officer shapes CITIC...
SEHK:1672
SEHK:1672Biotechs

Ascletis Pharma (SEHK:1672) Is Up 5.4% After HK$844m Follow-On Offering And Positive Phase III Acne Data - Has The Bull Case Changed?

Ascletis Pharma recently filed a follow-on equity offering of HK$843.54 million via a subsequent direct listing, issuing 69,256,000 ordinary shares at HK$12.18 each. The fundraising follows positive Phase III data for denifanstat in moderate-to-severe acne and progress with ASC30 in metabolic disease, underscoring Ascletis’s late-stage pipeline momentum. We’ll now explore how this combination of positive Phase III acne data and a sizable equity raise shapes Ascletis Pharma’s investment...